Fox Run Management L.L.C. Buys Shares of 16,665 AxoGen, Inc. $AXGN

Fox Run Management L.L.C. purchased a new stake in AxoGen, Inc. (NASDAQ:AXGN) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 16,665 shares of the medical equipment provider’s stock, valued at approximately $297,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Future Financial Wealth Managment LLC purchased a new position in AxoGen during the third quarter valued at approximately $27,000. State of Alaska Department of Revenue bought a new stake in AxoGen during the 3rd quarter valued at $43,000. Tower Research Capital LLC TRC increased its holdings in shares of AxoGen by 189.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after acquiring an additional 3,327 shares during the period. AlphaQuest LLC raised its position in shares of AxoGen by 882.2% in the 2nd quarter. AlphaQuest LLC now owns 6,276 shares of the medical equipment provider’s stock worth $68,000 after acquiring an additional 5,637 shares in the last quarter. Finally, State of Wyoming bought a new position in shares of AxoGen in the 2nd quarter worth $69,000. 80.29% of the stock is currently owned by institutional investors.

AxoGen Stock Down 3.4%

NASDAQ:AXGN opened at $30.65 on Tuesday. The company has a current ratio of 5.11, a quick ratio of 3.31 and a debt-to-equity ratio of 0.51. AxoGen, Inc. has a twelve month low of $9.22 and a twelve month high of $36.00. The company has a market cap of $1.59 billion, a PE ratio of -90.14 and a beta of 0.98. The company’s 50 day moving average is $33.04 and its two-hundred day moving average is $25.33.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Tuesday, February 24th. The medical equipment provider reported $0.07 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.01). The company had revenue of $59.90 million for the quarter, compared to analyst estimates of $59.90 million. AxoGen had a negative return on equity of 13.44% and a negative net margin of 6.97%. Analysts anticipate that AxoGen, Inc. will post -0.29 EPS for the current year.

Insider Activity at AxoGen

In other AxoGen news, CFO Lindsey Marie Hartley sold 14,812 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $29.86, for a total transaction of $442,286.32. Following the sale, the chief financial officer owned 31,376 shares in the company, valued at approximately $936,887.36. The trade was a 32.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul Thomas sold 21,399 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $29.61, for a total value of $633,624.39. Following the completion of the transaction, the director directly owned 13,528 shares in the company, valued at $400,564.08. This represents a 61.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 301,680 shares of company stock worth $9,174,052 in the last quarter. 2.78% of the stock is owned by insiders.

Analysts Set New Price Targets

AXGN has been the topic of several analyst reports. Citizens Jmp lifted their target price on AxoGen from $34.00 to $42.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 24th. Citigroup restated an “outperform” rating on shares of AxoGen in a report on Tuesday, February 24th. Wells Fargo & Company began coverage on shares of AxoGen in a research note on Thursday, February 19th. They set an “overweight” rating and a $40.00 price objective for the company. Canaccord Genuity Group raised their target price on shares of AxoGen from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Finally, Mizuho assumed coverage on shares of AxoGen in a report on Monday, December 1st. They issued an “outperform” rating and a $40.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, AxoGen currently has an average rating of “Moderate Buy” and a consensus target price of $37.67.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.